HIV integrase and HIV protease — Drug Target

All drugs that target HIV integrase and HIV protease — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Antiretroviral combination (integrase inhibitor + protease inhibitor)

Marketed (1)

• Raltegravir and Atazanavir · Peter J. Ruane, M.D., Inc. · Antiretroviral combination (integrase inhibitor + protease inhibitor) · Infectious Disease / Virology
  This combination inhibits HIV replication by blocking integrase (raltegravir) and protease (atazanavir), preventing viral DNA integration and polyprotein processing.